A monoclonal antibody targeting CD74 (milatuzumab) has received US FDA approval for multiple myeloma [149], a malignancy of B cells where MIF–CD74 survival pathways are highly active [150]. The gene discussed is CD74; the disease is plasma cell myeloma.